Staveley Aimee, Soosay Ian, O'Brien Anthony J
Research Student, School of Nursing, University of Auckland, Auckland.
Honorary Academic, Faculty of Medical and Health Sciences, University of Auckland, Auckland.
N Z Med J. 2017 Nov 10;130(1465):44-52.
To audit New Zealand district health boards' (DHBs) metabolic monitoring policies in relation to consumers prescribed second-generation antipsychotic medications using a best practice guideline.
Metabolic monitoring policies from DHBs and one private clinic were analysed in relation to a best practice standard developed from the current literature and published guidelines relevant to metabolic syndrome.
Fourteen of New Zealand's 20 DHBs currently have metabolic monitoring policies for consumers prescribed antipsychotic medication. Two of those policies are consistent with the literature-based guideline. Eight policies include actions to be taken when consumers meet criteria for metabolic syndrome. Four DHBs have systems for measuring their rates of metabolic monitoring. There is no consensus on who is clinically responsible for metabolic monitoring.
Metabolic monitoring by mental health services in New Zealand reflects international experience that current levels of monitoring are low and policies are not always in place. Collaboration across the mental health and primary care sectors together with the adoption of a consensus guideline is needed to improve rates of monitoring and reduce current rates of physical health morbidities.
使用最佳实践指南，审核新西兰地区卫生委员会（DHBs）针对使用第二代抗精神病药物的消费者的代谢监测政策。
根据从当前文献和已发表的与代谢综合征相关的指南中制定的最佳实践标准，分析了DHBs和一家私人诊所的代谢监测政策。
新西兰20个DHBs中有14个目前针对使用抗精神病药物的消费者制定了代谢监测政策。其中两项政策与基于文献的指南一致。八项政策包括消费者符合代谢综合征标准时应采取的行动。四个DHBs有测量其代谢监测率的系统。关于谁在临床上负责代谢监测尚无共识。
新西兰心理健康服务机构的代谢监测反映了国际经验，即目前的监测水平较低且政策并不总是到位。需要心理健康和初级保健部门之间的合作以及采用共识指南，以提高监测率并降低当前的身体健康发病率。
